In non-responders , fibrosis progression rate decreased from 0.25 Metavir unit ( 0.17-0 .33 ) before treatment to 0 ( 0-0 ) during treatment ( P = 0.002 ) and from 0.63 SFS unit ( 0.49-1 .12 ) to 0 ( -2.67 -1.33 ) ( P = 0.18 ) .
